Targeted drug duo tested for tough blood cancers
NCT ID NCT04874194
Summary
This study tested a combination of two drugs, omacetaxine and venetoclax, for adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or stopped responding to treatment, and who have a specific genetic change called RUNX1. The goal was to find the safest, most effective dose and see if the combination could help control these aggressive blood cancers. The trial was terminated early and enrolled 24 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.